Video
Author(s):
“We want to make sure that if it is an efficacious medicine for that patient to consider using a generic formulation,” says Kelvin A. Moses, MD, PhD, FACS.
In this video, Kelvin A. Moses, MD, PhD, FACS, discusses the topics and advice from his presentation, “Financial and toxicity considerations when managing advanced PCa,” presented recently at the 2021 Society of Urologic Oncology Annual Meeting. Moses is an associate professor of urology and fellowship director of urologic oncology at the Vanderbilt University Medical Center in Nashville, Tennessee.